Commercially available AT1R antibodies may lack the specificity required to accurately quantify receptor expression in basic science research.
Answers are grounded in this paper and cite their sources.
Questions reliability of prior AT1R expression data from commercial antibodies; leaves open validated quantification methods in hypertension research.
We agree with the report by Herrera et al 1 demonstrating that antiangiotensin II type-1 receptor (AT 1 R) antibodies that are commonly used exhibit nonspecific binding that may lead to erroneous results.Because only 3 AT 1 R antibodies were used in the study, we would like to share our findings to support their conclusion.Antihemagglutinin antibody detected a major band (≈40 kDa) in human embryonic kidney cells expressing rat AT 1A R fused with hemagglutinin tag at either amino terminus or carboxyl terminus but not in the control cells.The molecular weight is consistent with the AT 1A R band observed by Herrera et al. 1 In contrast, no specific difference was observed among the cell lysates immunoblotted with 3 distinct AT 1 R antibodies, which should have detected rat AT 1A R according to the manufacturers (Figure ).Herrera et al 1 used mouse tissues and cells expressing mouse AT 1A R for their experiments.Our data support and expand the findings by including rat AT 1A R and adding 2 other frequently used AT 1 R antibodies.Researchers must be aware that commercially available AT 1 R antibodies and antibodies against other G protein-coupled receptors may not be specific enough to quantify the receptor expression.To publish an article using an AT 1 R antibody, it should be accompanied by sufficient evidence to support the specificity.We also encourage the antibody manufacturers to include rigorous confirmation before commercialization.
No takes yet. Share an insight, caveat, or question.
Elliott et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: